Lecrubier Y
INSERM Unité 302, Hôpital de La Salpêtrière, Paris, France.
Int Clin Psychopharmacol. 1995 Mar;10 Suppl 2:29-35. doi: 10.1097/00004850-199503002-00006.
The newer antidepressants have clearly shown themselves to be safer and to have a more acceptable side effect profile than the traditional antidepressants. Greater patient acceptability has important consequences in relation to efficacy, in that compliance is likely to be better in the long term. One of the newest antidepressants, the serotonin- noradrenaline reuptake inhibitor venlafaxine, has neurobiologic properties that recommend it for clinical use by both the psychiatrist and the general practitioner. Controlled studies have confirmed the overall utility of this agent in treating a range of depressive subtypes, such as moderate depression and severe endogenous depression, with a low risk of serious adverse events and an excellent tolerability profile. In addition, venlafaxine has shown a dose-response relationship for efficacy, offering the possibility of a wide dose range, which may be suitably employed in different clinical situations.
新型抗抑郁药已明确显示出比传统抗抑郁药更安全，且副作用方面更易让人接受。患者更高的接受度对疗效有重要影响，因为从长远来看，依从性可能会更好。最新的抗抑郁药之一，5-羟色胺-去甲肾上腺素再摄取抑制剂文拉法辛，具有神经生物学特性，这使得精神科医生和全科医生都推荐将其用于临床。对照研究已证实该药物在治疗一系列抑郁亚型（如中度抑郁和重度内源性抑郁）方面的总体效用，严重不良事件风险低，耐受性良好。此外，文拉法辛已显示出疗效的剂量反应关系，提供了广泛的剂量范围，可适用于不同的临床情况。
